David A. Siegel Chemo Centryx, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $2.42 Million - $5.66 Million	-109,300 Reduced 69.78%	47,341 $2.45 Million
Q2 2022 Aug 15, 2022	SELL	$15.36 - $27.51 $972,288 - $1.74 Million	-63,300 Reduced 28.78%	156,641 $3.88 Million
Q1 2022 May 16, 2022	BUY	$22.22 - $39.12 $3.02 Million - $5.31 Million	135,800 Added 161.4%	219,941 $5.51 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $1.55 Million - $3.41 Million	84,141 New	84,141 $3.06 Million
Q3 2021 Nov 15, 2021	SELL	$13.18 - $19.83 $150,792 - $226,875	-11,441 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$9.59 - $50.88 $199,472 - $1.06 Million	-20,800 Reduced 64.51%	11,441 $153,000
Q1 2021 May 17, 2021	SELL	$49.53 - $68.4 $8.42 Million - $11.6 Million	-170,000 Reduced 84.06%	32,241 $1.65 Million
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $3.67 Million - $5.06 Million	-77,700 Reduced 27.76%	202,241 $12.5 Million
Q3 2020 Nov 16, 2020	BUY	$46.35 - $61.69 $1.94 Million - $2.58 Million	41,900 Added 17.6%	279,941 $15.3 Million
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $3.76 Million - $6.34 Million	97,500 Added 69.37%	238,041 $13.7 Million
Q1 2020 May 15, 2020	SELL	$32.73 - $50.78 $1.84 Million - $2.85 Million	-56,100 Reduced 28.53%	140,541 $5.65 Million
Q4 2019 Feb 14, 2020	SELL	$6.81 - $39.55 $619,710 - $3.6 Million	-91,000 Reduced 31.64%	196,641 $7.78 Million
Q3 2019 Nov 14, 2019	SELL	$6.47 - $8.96 $157,221 - $217,728	-24,300 Reduced 7.79%	287,641 $1.95 Million
Q2 2019 Aug 14, 2019	BUY	$8.31 - $14.85 $609,322 - $1.09 Million	73,324 Added 30.73%	311,941 $2.9 Million
Q1 2019 May 15, 2019	BUY	$10.01 - $13.89 $233,993 - $324,692	23,376 Added 10.86%	238,617 $3.31 Million
Q4 2018 Feb 14, 2019	SELL	$9.15 - $12.26 $118,035 - $158,154	-12,900 Reduced 5.65%	215,241 $2.35 Million
Q3 2018 Nov 14, 2018	SELL	$10.49 - $13.72 $277,985 - $363,580	-26,500 Reduced 10.41%	228,141 $2.88 Million
Q2 2018 Aug 14, 2018	BUY	$10.62 - $13.98 $2.42 Million - $3.18 Million	227,441 Added 836.18%	254,641 $3.35 Million
Q1 2018 May 15, 2018	BUY	$5.9 - $14.99 $85,550 - $217,355	14,500 Added 114.17%	27,200 $370,000
Q3 2017 Nov 14, 2017	BUY	$6.5 - $10.69 $82,550 - $135,763	12,700	12,700 $94,000

Others Institutions Holding CCXI

# of Institutions

Shares Held

66.3K

Call Options Held

Put Options Held

View Full List

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account